KRAS Mutation Testing in Advanced Colorectal Cancers

Main Article Content

Shanop Shuangshoti, MD

Abstract

KRAS is an oncogene located on the short arm of chromosome 12 (12p12.1). The gene is a member of the Ras family of small guanine nucleotide–binding proteins, first identified as a cellular homolog of a  transforming gene in the Kirsten rat sarcoma virus.1 Activating mutations in KRAS have been noted in a variety of human cancers,  including carcinomas of the pancreas, lung (non-small cell lung cancer), and colorectum (Table 1). KRAS mutations are frequently found in exon 1 (codons 12 and 13) and exon 2 (codon 61).2 Mutations in KRAS codons 12 and 13 have been associated with lack of response to EGFR-targeted therapies in patients with colorectal cancer (CRC)(Table 2).

Article Details

How to Cite
1.
Shuangshoti S. KRAS Mutation Testing in Advanced Colorectal Cancers. BKK Med J [Internet]. 2011 Feb. 18 [cited 2024 Oct. 13];1(1):63. Available from: https://he02.tci-thaijo.org/index.php/bkkmedj/article/view/217665
Section
Reviews Article

References

1. Wang HL, et al. KRAS mutation testing in human cancers: the pathologist’s role in the era of personalized medicine. Adv Anat Pathol 2010;17:23-32
2. Whitehall V, et al. A Multicenter blinded study to evalu- ate KRAS mutation testing methodologies in the clinical setting. J Mol Diagn 2009;11:543-552
3. Lièvre A, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26: 374-379
4. Amado RG. Wild-type KRAS is required for panitumu- mab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-1634
5. Allegra CJ, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carci- noma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009;27:2091-2096
6. Monzon FA, et al. The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. Arch Pathol Lab Med 2009;133:1600-1606